{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:48Z","timestamp":1787003748517,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Background: Lymph node (LN) involvement, as an important prognostic factor in breast cancer (BC) patients, has a crucial role in their therapeutic approach. Consequently, a great desire is to thoroughly assess the patients based on their axillary LN status. The present study evaluated the characteristics and survival rate of axillary metastatic BC patients in a Tertiary and referral center. Method: The overall survival, disease-free survival, and clinicopathological characteristics of axillary metastatic BC patients referred to the Cancer Research Center in Tehran, Iran, from 1991 to 2022 were assessed retrospectively. We obtained patients\u2019 clinical data from prospectively maintained registries. Result: Among the total 3399 recruited patients, 49.1%, 26.3%,13.1%, and 6.4% were pN0, pN1, pN2 and pN3, respectively. The pN0 group patients showed a significantly lower Hazard Ratio (HR) for DFS and OS compared to others. Moreover, estrogen and progesterone receptors, human epidermal growth factor2, tumor pathology type and tumor grade were prognostic factors of axillary LN status. Accordingly, pN0 patients had a lower recurrence risk than the others (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01). Conclusion: The axillary lymph node status has been considered as one of the fundamental factors determining the therapeutic strategy and prognosis of BC patients, which has an association with tumor characteristics. Regarding the crucial impact of the LN status on the survival landscape of breast cancer patients, accurate detection of the involved one and close screening follow-up of patients with more metastatic LNs during the surgery have a high value.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-84115-7","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:25:57Z","timestamp":1738880757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study"],"prefix":"10.1038","volume":"15","author":[{"given":"Seyed Mohamad Sadegh","family":"Mousavi-kiasary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdis","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Abbasvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batoul","family":"Khoundabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Bagherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsoon","family":"Zandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Honarvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Esmaeil","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"1","key":"84115_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0828-0","volume":"12","author":"N Li","year":"2019","unstructured":"Li, N. et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: Results from the global burden of disease study 2017. J. Hematol. Oncol. 12 (1), 1\u201312 (2019).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"84115_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(20)30580-5","volume":"22","author":"P Dubsky","year":"2021","unstructured":"Dubsky, P. et al. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: The Lucerne toolbox. Lancet Oncol. 22 (1), e18\u2013e28 (2021).","journal-title":"Lancet Oncol."},{"key":"84115_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10549-020-05830-z","volume":"183","author":"J Hotton","year":"2020","unstructured":"Hotton, J. et al. Pre-operative axillary ultrasound with fine-needle aspiration cytology performance and predictive factors of false negatives in axillary lymph node involvement in early breast cancer. Breast Cancer Res. Treat. 183, 639\u2013647 (2020).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"84115_CR4","first-page":"393","volume":"36","author":"T Fujii","year":"2016","unstructured":"Fujii, T. et al. Implication of 18F-fluorodeoxyglucose uptake of affected axillary lymph nodes in cases with breast cancer. Anticancer Res. 36 (1), 393\u2013397 (2016).","journal-title":"Anticancer Res."},{"issue":"3","key":"84115_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.breast.2013.02.001","volume":"22","author":"W Gatzemeier","year":"2013","unstructured":"Gatzemeier, W. & Mann, G. B. Which sentinel lymph-node (SLN) positive Breast cancer patient needs an axillary lymph-node dissection (ALND)\u2013ACOSOG Z0011 results and beyond. Breast 22 (3), 211\u2013216 (2013).","journal-title":"Breast"},{"issue":"1","key":"84115_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000505957","volume":"15","author":"C Thomssen","year":"2020","unstructured":"Thomssen, C. et al. International consensus conference for advanced breast cancer, Lisbon 2019: ABC5 consensus\u2013assessment by a German group of experts. Breast Care. 15 (1), 82\u201395 (2020).","journal-title":"Breast Care"},{"issue":"1","key":"84115_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.47717\/turkjsurg.2023.5984","volume":"39","author":"J \u017dateck\u00fd","year":"2023","unstructured":"\u017dateck\u00fd, J. et al. Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging. Turkish J. Surg. 39 (1), 1 (2023).","journal-title":"Turkish J. Surg."},{"issue":"1","key":"84115_CR8","first-page":"65","volume":"94","author":"Y Wasuthit","year":"2011","unstructured":"Wasuthit, Y. et al. Predictive factors of axillary lymph node metastasis in breast cancer. J. Med. Assoc. Thai. 94 (1), 65 (2011).","journal-title":"J. Med. Assoc. Thai."},{"issue":"4","key":"84115_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.13189\/cor.2014.020402","volume":"2","author":"EM Ali","year":"2014","unstructured":"Ali, E. M., Ahmed, A. R. & Ali, A. M. Correlation of breast cancer subtypes based on ER, PR and HER2 expression with axillary lymph node status. Cancer Oncol. Res. 2 (4), 51\u201357 (2014).","journal-title":"Cancer Oncol. Res."},{"key":"84115_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7819-6-112","volume":"6","author":"L Ayadi","year":"2008","unstructured":"Ayadi, L. et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J. Surg. Oncol. 6, 1\u20138 (2008).","journal-title":"World J. Surg. Oncol."},{"issue":"1\u20132","key":"84115_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3121\/cmr.2008.825","volume":"7","author":"AA Onitilo","year":"2009","unstructured":"Onitilo, A. A. et al. Breast cancer subtypes based on ER\/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin. Med. Res. 7 (1\u20132), 4\u201313 (2009).","journal-title":"Clin. Med. Res."},{"issue":"24","key":"84115_CR12","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1200\/JCO.2006.08.8013","volume":"25","author":"JLB Bevilacqua","year":"2007","unstructured":"Bevilacqua, J. L. B. et al. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J. Clin. Oncol. 25 (24), 3670\u20133679 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"84115_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/bjs.5943","volume":"95","author":"A Pal","year":"2008","unstructured":"Pal, A. et al. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. J. Br. Surg. 95 (3), 302\u2013309 (2008).","journal-title":"J. Br. Surg."},{"issue":"4","key":"84115_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.amjsurg.2005.06.008","volume":"190","author":"AC Degnim","year":"2005","unstructured":"Degnim, A. C. et al. Nonsentinel node metastasis in breast cancer patients: Assessment of an existing and a new predictive nomogram. Am. J. Surg. 190 (4), 543\u2013550 (2005).","journal-title":"Am. J. Surg."},{"issue":"18","key":"84115_CR15","first-page":"4064","volume":"115","author":"JS Scow","year":"2009","unstructured":"Scow, J. S. et al. Assessment of the performance of the Stanford Online calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer Interdiscip. Int. J. Am. Cancer Soc. 115 (18), 4064\u20134070 (2009).","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"issue":"4","key":"84115_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejso.2006.09.003","volume":"33","author":"N Patani","year":"2007","unstructured":"Patani, N., Dwek, M. & Douek, M. Predictors of axillary lymph node metastasis in breast cancer: A systematic review. Eur. J. Surg. Oncol. (EJSO). 33 (4), 409\u2013419 (2007).","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"issue":"7","key":"84115_CR17","doi-asserted-by":"publisher","first-page":"9936","DOI":"10.3390\/s120709936","volume":"12","author":"F Xie","year":"2012","unstructured":"Xie, F. et al. A logistic regression model for predicting axillary lymph node metastases in early breast carcinoma patients. Sensors 12 (7), 9936\u20139950 (2012).","journal-title":"Sensors"},{"issue":"3","key":"84115_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.breast.2012.09.003","volume":"22","author":"E Yoshihara","year":"2013","unstructured":"Yoshihara, E. et al. Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast 22 (3), 357\u2013361 (2013).","journal-title":"Breast"},{"issue":"1","key":"84115_CR19","first-page":"50","volume":"16","author":"MA Nouh","year":"2004","unstructured":"Nouh, M. A. et al. Lymph node metastasis in breast carcinoma: Clinicopathological correlations in 3747 patients. J. Egypt. Natl. Canc Inst. 16 (1), 50\u201356 (2004).","journal-title":"J. Egypt. Natl. Canc Inst."},{"issue":"1","key":"84115_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7314\/APJCP.2012.13.1.251","volume":"13","author":"L Li","year":"2012","unstructured":"Li, L. & Chen, L. Z. Factors influencing axillary lymph node metastasis in invasive breast cancer. Asian Pac. J. Cancer Prev. 13 (1), 251\u2013254 (2012).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"84115_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-228","volume":"10","author":"K Bauer","year":"2010","unstructured":"Bauer, K., Parise, C. & Caggiano, V. Use of ER\/PR\/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 10, 1\u201312 (2010).","journal-title":"BMC Cancer"},{"issue":"5","key":"84115_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/00000658-199911000-00012","volume":"230","author":"C Gajdos","year":"1999","unstructured":"Gajdos, C., Tartter, P. I. & Bleiweiss, I. J. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann. Surg. 230 (5), 692 (1999).","journal-title":"Ann. Surg."},{"issue":"12","key":"84115_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1046\/j.1445-1433.2001.02266.x","volume":"71","author":"B Chua","year":"2001","unstructured":"Chua, B. et al. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J. Surg. 71 (12), 723\u2013728 (2001).","journal-title":"ANZ J. Surg."},{"key":"84115_CR24","doi-asserted-by":"crossref","unstructured":"Chen, H. et al. Correlation analysis of pathological features and axillary lymph node metastasis in patients with invasive breast cancer. J. Immunol. Res. 2022 (2022).","DOI":"10.1155\/2022\/7150304"},{"issue":"5","key":"84115_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4067\/S0034-98872019000500557","volume":"147","author":"D Kusti\u0107","year":"2019","unstructured":"Kusti\u0107, D. et al. Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. Rev. Med. Chil. 147 (5), 557\u2013567 (2019).","journal-title":"Rev. Med. Chil."},{"issue":"6","key":"84115_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1075-122X.2005.00125.x","volume":"11","author":"R Prati","year":"2005","unstructured":"Prati, R. et al. Histopathologic characteristics predicting HER-2\/neu amplification in breast cancer. Breast J. 11 (6), 433\u2013439 (2005).","journal-title":"Breast J."},{"key":"84115_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr1200","volume":"7","author":"NM Almasri","year":"2005","unstructured":"Almasri, N. M. & Hamad, M. A. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res. 7, 1\u20137 (2005).","journal-title":"Breast Cancer Res."},{"issue":"2","key":"84115_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/02841860701678761","volume":"47","author":"I Lale Atahan","year":"2008","unstructured":"Lale Atahan, I. et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol. 47 (2), 232\u2013238 (2008).","journal-title":"Acta Oncol."},{"key":"84115_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10147-011-0207-5","volume":"16","author":"JS Lee","year":"2011","unstructured":"Lee, J. S. et al. Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. Int. J. Clin. Oncol. 16, 473\u2013481 (2011).","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"84115_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10549-023-07089-6","volume":"202","author":"B Costeira","year":"2023","unstructured":"Costeira, B. et al. Long-term locoregional recurrence in patients treated for breast cancer. Breast Cancer Res. Treat. 202 (3), 551\u2013561 (2023).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"84115_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.31557\/APJCP.2020.21.1.185","volume":"21","author":"M Konieczny","year":"2020","unstructured":"Konieczny, M. et al. Quality of life of women with breast cancer and socio-demographic factors. Asian Pac. J. Cancer Prevent. APJCP. 21 (1), 185 (2020).","journal-title":"Asian Pac. J. Cancer Prevent. APJCP"},{"issue":"3","key":"84115_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.breast.2012.02.006","volume":"21","author":"N Ibrahim","year":"2012","unstructured":"Ibrahim, N. & Oludara, M. Socio-demographic factors and reasons associated with delay in breast cancer presentation: a study in Nigerian women. Breast 21 (3), 416\u2013418 (2012).","journal-title":"Breast"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84115-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:26:04Z","timestamp":1738880764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84115-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84115"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84115-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study got the code number from the ethics committee, which was supported by the deputy of research and technology at Shahid Beheshti University of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"4571"}}